OR WAIT null SECS
Will produce plasmid DNA-based therapies, mRNA vaccine materials
Thermo Fisher Scientific Inc, a contract development and manufacturing organization (CDMO), has opened a new 67,000 square-foot current good manufacturing practice (cGMP) plasmid DNA (pDNA) manufacturing facility on its Carlsbad, CA campus, allowing it to meet the rising demand for pDNA-based therapies and mRNA-based vaccines.
pDNA can be used as a therapeutic agent in gene therapies and certain vaccines. Some of its advantages include weak immunogenicity, increased safety and ease of manufacture.
"Demand for commercial plasmid DNA is outpacing supply as the development of transformative gene therapies and vaccines accelerates globally," says Marc N. Casper, chairman, president and CEO of Thermo Fisher Scientific. "Investments in state-of-the-art manufacturing such as this ensure that our customers have reliable access to the high-quality materials and capabilities that have become vital for the production of these new lifesaving medicines and the patients in need."
As manufacturing increases, Thermo Fisher will be adding more than 150 new positions.